Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple combination antiviral therapy versus oseltamivir for influenza A in immunocompromised patients
ACTRN12609000708257Phase 2Terminated
- Sponsor
- Adamas Pharmaceuticals, Inc.
- Start
- Aug 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of amantadine, ribavirin and oseltamivir in Influenza A infection (2 arms), sponsored by Adamas Pharmaceuticals, Inc. Primary endpoint: Viral shedding clearance by quantitative RT-PCR. Started Aug 2009; status: terminated.
02
Drugs
amantadineribavirinoseltamivir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on ACTRN12609000708257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000708257.